Craniospinal Irradiation in Histone AlteRed Midline Glioma

Recruiting N/A Interventional Study
Glioma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
3 – 18
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
32 (estimated)
Sponsor
Tata Memorial Centre · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Paediatric H3K27/H3G34 mutant diffuse midline gliomas are high grade gliomas that arise in midline structures/cerebral hemispheres and are known to have dismal outcomes. Standard treatment includes definitive radiation therapy to primary site along with concurrent temozolomide chemotherapy following histological confirmation with a biopsy. Studies have shown poorer outcomes in the paediatric age g…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Newly diagnosed biopsy proven histone altered diffuse midline glioma 2. Age- ≥3 to \<18 years at time of diagnosis 3. Karnofsky/Lansky Performance Score more than or equal to 70 4. Has provided written informed consent/ assent form 5. No prior therapy except debulking surgery…
Contacts

Abhishek Chatterjee, MD

2224177000

chatterji08@gmail.com

CONTACT